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Abstract 
 
The incidence of many cancer types is significantly higher in the male than female 
populations, with associated differences in survival. Occupational and/or behavioral 
factors are well known underlying determinants. However, cellular/molecular 
differences between the two sexes are also likely to be important. We are focusing 
here on the complex interplay that sexual hormones and sex chromosomes can have 
in intrinsic control of cancer initiating cell populations, tumor microenvironment 
and systemic determinants of cancer development like the immune system and 
metabolism. A better appreciation of these differences between the two sexes could 
be of substantial value for cancer prevention as well as treatment. 
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Introduction (Epidemiology) 
 
 Epidemiological studies point to sexual dimorphism as a relevant factor for 
cancer incidence and survival. Overall, females have a lesser risk and better 
prognosis than males in a wide range of cancer types unrelated to reproductive 
function, such as those of colon, skin, head/neck, esophagus, lung and liver 1, 2 
(Figure 1). Only very few exceptions exist in which incidence is higher in women, 
specifically thyroid cancer 3. Noteworthy, this trend is observed independently to 
the ethnicity of the studied population. 
 The generally higher cancer risk in the male population was previously 
attributed to environmental exposure to chemicals or carcinogens, diet and risk 
behaviors such as smoking and drinking. However, even after appropriate 
adjustment for risk factors and statistical evaluation of the data, females still exhibit 
a higher degree of overall cancer protection than males 4, 5, with significant 
differences existing also in some childhood malignancies, specifically acute T cell 
lymphoblastic leukemia and hepatoblastoma 6. This review investigates the possible 
cellular/molecular basis of differences in cancer susceptibility between the two 
sexes, focusing on the complex impact that sexual hormones and sex chromosomes 
can have in this context. Importantly, a significant interplay is likely to exist between 
the two, which could be of value for novel forms of cancer prevention and 
intervention. 
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General impact of sex-related hormone signaling in cells and organ systems 
unrelated to reproductive function 
 
 Both steroid and protein hormones are involved in sexual development and 
reproductive functions. Starting around birth, gonadal steroids control production 
of protein hormones, so called “somatotrophs”, by the hypothalamus-pituitary axis 
with a more pronounced impact in puberty and adulthood. Sex-related 
somatotrophs with a direct sex-related function, such as prolactin (PRL), luteinizing 
hormone (LH), follicle-stimulating hormone (FSH) and gonadotropin-releasing 
hormone (GnRH) are mainly implicated in cancer of reproductive tissues, like 
prostate, ovarian and breast 7-9. However, as detailed further below, prolactin 
impinges also on cancer development in non-reproductive organs, specifically the 
liver 10, 11. Among other somatotrophs with a broader function, growth hormone 
(GH) has been similarly implicated in liver cancer 12. GH affects liver gene 
expression differentially in the two genders, possibly in connection with its pulsatile 
secretion into the plasma in men and constant in women 13.  Beside its action in the 
liver, GH has been implicated in tumorigenesis of other several tissues, like breast, 
prostate, colon, skin, endometrium and brain, even if in these cases autocrine GH 
production by cancer cells may be more important than pituitary secretion 14. 
Relative to protein hormones, much more abundant information exists on the 
impact of sex steroid hormones on cancer development in non reproductive organs. 
These hormones, being lipid soluble, can enter the plasma membrane of target cells 
and interact directly with intracellular receptors that can shuttle to the nucleus to 
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affect gene expression 15. Action of these hormones extends at the epigenetic level to 
DNA methylation and chromatin conformation 16, 17. Analysis of gene expression in 
different non reproductive tissues indicates the existence of a gender specific 
influence on transcription 18, 19, which is paralleled at the level of chromatin 
organization, by specific differences between the sexes 20. As discussed here below, 
sex hormone signaling pathways are likely to affect cancer susceptibility through 
multiple mechanisms, impacting on intrinsic self renewal mechanisms, tumor 
microenvironment, immune system and metabolism. The vast majority of accrued 
information relates to the involvement of three major sex steroid hormone 
receptors, estrogen receptor (ER) α, β and androgen receptor (AR), on which we 
will be focusing (Fig. 2). It is important to note, however, that the progesterone 
receptor, under intense investigation in breast cancer 21, may also be involved in 
cancer of non-reproductive organs, like what recently reported for lung NSCLC 22 
and colon cancer 23.  
 
a) Stem cell renewal : Specific ablation of estrogen receptor α, β and androgen 
receptor affects homeostasis and/or regeneration of organs unrelated to 
reproductive functions, such as lung 24,, colon 25 and skin 26-28. Sex steroids have an 
impact on stem cell populations of various types. Estrogens enhance self renewal of 
embryonic stem cells 29, promote endothelial progenitor cells 30 and, during 
pregnancy, contribute to the expansion of hematopoietic stem cell populations 31. 
Neural stem cells have been reported to fluctuate during the estrous cycle and 
exogenous estrogen administration is sufficient to increase neural stem cell division 
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32. 17β-estradiol, the most potent form of estrogen, can also counteract senescence 
through p53-antagonizing mechanisms and/or control of telomerase expression 33, 
34.  
 Like estrogens, androgens are involved in control of hematopoietic cell 
renewal. Aging men, that experience a reduction in androgen production, are prone 
to develop normocitic anemia, a condition characterized by a reduced number of red 
blood cells, that can be corrected with androgen supplementation 35. Androgen 
supplementation has also ameliorating effects on acquired aplastic anemia, 
characterized by a reduced production of all blood cells, and dyskeratosis congenita, 
a genetic syndrome interesting several parts of the body 36, 37. These two diseases 
manifest telomere dis-function, bone marrow failure due to hematopoietic stem 
cells impairment and are linked to cancer development. Molecularly, in primary 
hematopoietic cells, androgens induce telomerase expression through aromatase-
dependent conversion of testosterone into estrogen and ERα activation 38.  
 The role of ERα signaling in breast cancer initiating cells is an area of active 
investigation 39, 40, and so is that of AR in prostate cancer 41, 42. By contrast, the role 
that these pathways play in self-renewal of initiating cancer cells of other types is a 
mostly unexplored topic and important area of future investigation. 
 
b) Cancer stroma : The tumor microenvironment plays a crucial role in both 
initiation and progression of the disease  43, 44. Various components of the stromal 
compartment are under sex hormone control. Still not well depicted is the impact of 
sex hormones on the behavior of stromal fibroblasts. Cancer Associated Fibroblasts 
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(CAFs) can be viewed like persistently activated fibroblasts sharing properties with 
fibroblasts at wound sites 44. While well known differences exist in skin wound 
healing between the two sexes 26, 27, where fibroblasts exert an important role in the 
first phases of the process, studies on the impact of sex hormones on CAF function 
have mostly focused on prostate 45-47, breast 48, 49 and cervical cancer 50 types. 
Estrogens were shown to promote mobilization of bone marrow derived precursors 
to breast cancer stroma 48 and increase stromal density 49. In cervical cancer, ERα 
expression in stromal fibroblasts is sustained during the course of the disease 50, 
pointing to a possibly detrimental role. By contrast, in prostate tumors, expression 
of ERα is positively associated with survival and restrains cancer associated 
fibroblast behavior reducing angiogenesis and tumor growth 45. Such beneficial role 
contrasts with additional observations that implicate ERα activity as a positive 
regulator of prostate epithelial cells 51, suggesting that this receptor functions 
differently in the two compartments. By contrast to ERα, ERβ activation has been 
reported to restrain prostate hyperplasia and cancer by inducing cell death of both 
epithelial and stromal cells 52. 
 Conflicting results exist concerning the role of AR signaling in prostate CAFs. 
While animal model studies indicate that this receptor in stromal fibroblasts 
promotes initial stages of the disease 46, clinical evidence points to the opposite 
possibility that sustained AR expression in this context is linked to less aggressive 
cancer and better prognosis 47. 
 Angiogenesis is another key determinant of cancer development. Estrogens 
have a well established pro-angiogenesis function, best known in the endometrium 
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during the female reproductive cycle, which is mediated by enhancement of 
endothelial cell proliferation and migration 30, 53. This is mediated by diffusible 
factors like PAF 54 and VEGF 55, which are frequently secreted by cancer cells in 
response to estrogens. In contrast to ERα, ERβ activation in neoplastic breast cells 
negatively affects blood vessel formation 56. Androgens also stimulate endothelial 
cell migration and new blood vessel formation through VEGF, especially in cells 
taken from male tissues, due to higher AR expression 57.  
 As for cancer initiating cells, the role that ER and AR signaling play in the 
stromal compartment of tumors of non-reproductive systems is an area of great 
importance for future studies. 
 
c) Inflammatory/immune system :  The microenvironment encompasses different 
leukocyte populations, with macrophage M1 polarization playing a key role in 
chronic inflammation-associated cancer development 43. In macrophages, ERα 
significantly reduces their pro-inflammatory activity 58 and tumor promoting 
properties 59. In contrast, AR favors the migration of macrophages and the release of 
proinflammatory cytokines delaying wound healing 28. Mice lacking this receptor in 
inflammatory cells resolve the wound quicker than wild type mice. Macrophage 
release of cytokines is dependent on AR and contributes to prostate tumorigenesis 
60.  
 Besides macrophages, other cells of the myeloid and lymphoid lineages like 
neutrophils or lymphocytes express estrogen and androgen receptors and these sex 
hormones can modulate the immune system at multiple levels through control of 
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immune-modulatory genes like IFN-γ 61. Pathogenesis of autoimmune diseases, to 
which females are much more susceptible to than males, involves an altered 
balanced between effector T cells, with cytotoxic function, and regulatory 
(CD4+CD25+) T cells (Treg), a subpopulation of T cells that promotes self tolerance 
and restrains cancer immune surveillance 62. The Foxp3 transcription factor is a 
master regulator of Treg cell number and function 63. It belongs to the fork-head 
family of transcription factors and is encoded by the X-linked foxp3 gene. 
Polymorphisms and mutations of this gene are associated with a number of diseases 
with imuno-dysregulation and poly-endochrinopathies. foxp3 expression and 
function are under combined control of T cell receptor signaling and multiple 
cytokines through both transcription and post-transcription regulatory mechanisms 
63. In women, size of Treg cell populations positively correlates with estradiol levels 
during the luteal cycle and in pregnancy 61, with estradiol treatment inducing both 
Treg expansion and Foxp3 expression 64. Testosterone stimulation causes also a 
strong increase of Treg cells both in vivo and in vitro, through a mechanism that 
involves AR recruitment to the foxp3 locus and its enhanced expression 65.  
 The fact that both estrogens and androgens are involved in positive 
regulation of the foxp3 gene suggests that additional more indirect mechanisms are 
involved in the differential activity of Treg cells in the female versus male 
populations. One such mechanism may involve differential production and function 
of IL6. This cytokine, together with IL-1, promotes degradation of the Foxp3 protein 
and ensuing Treg suppression 66. Importantly, IL-6 expression is positively 
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regulated by estrogens 67 and genetic polymorphisms in the IL6 locus were 
identified that may be involved in its differential control between the two sexes 68.  
 
 Besides a differential impact on various cell populations, sex hormones can 
also affect the immune system indirectly, through the gut microbiome. In Non Obese 
Diabetic (NOD) mice, susceptible to autoimmune diabetes, the rise of testosterone 
after puberty promotes a divergent bacterial commensal population from adult 
females and prepuberal animals 69. Such effect, which is reversed upon castration, is 
associated with reduced susceptibility to autoimmune reaction linked with changes 
in cytokine expression in lymphoid and myeloid cells.   
 The X chromosome is also highly enriched in immune-related genes 61 and 
there are several X-linked microRNAs that may contribute to sex-specific regulation 
of the immune response by targeting immune-related genes 70, 71. In one study of an 
autoimmune disease, Systemic lupus erythematosus (SLE), several X-linked miRNAs 
were found overexpressed in T cells of female versus male patients 72. Several of the 
differentially expressed miRNAs are located within 5000bp of an estrogen response 
element and, among the predicted targets, was CBL, a negative regulator of T cell 
receptor activity, which is down-regulated in T cells of the SLE patients 72. 
Overall, a complex picture emerges whereby sexual dimorphism in the 
immune system is the combined result of multiple determinants 61. Irrespectively of 
the detailed mechanisms, the greater susceptibility of women to develop 
autoimmune diseases is likely accompanied by enhanced immune surveillance 
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against various tumor types.  As discussed at the end, further insights into this topic 
will likely lead to improved forms of cancer immune therapy and prevention. 
 
d) Metabolism : Steroid hormones are also central regulators of systemic 
metabolism, acting at several levels 73. Both estrogen and androgen receptors 
increase glucose tolerance and restrain visceral fat accumulation 74. Reduced ERα 
signaling in post-menopausal women and aromatase deficiency, with compromised 
conversion of androgens to estrogens, are associated with increased adiposity 73, a 
known risk factor for cancer development 75. Cancer is often associated with a 
severe body wasting syndrome called cachexia 76. Cachexia is a sexually dimorphic 
trait 77 that is linked to higher levels of autophagy in male hearts and is associated 
with reduced survival 78. Androgens have also an important muscle trophic function 
and the majority of male cancer patients in the seventh decade of life experiences 
sarcopenia, a condition characterized by the loss of muscle mass and strength, 
linked to a reduction in testosterone 79. A decrease in androgen levels has been 
noticed in multiple studies in male cancer patients 80 that may be a result of 
chemotherapy 81. Selective androgen modulators, able to activate AR mainly in the 
muscle, have been tested for their ability to revert or compensate for body mass 
wasting with improvement of lean body mass and physical condition 82.  
 
Sex hormone signaling in specific cancer types 
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 A clear example of greater cancer susceptibility of the male versus female 
populations due to hormonal sex influences is represented by hepatocellular 
carcinoma (HCC), which occurs more frequently in men 1, 2. A detailed analysis 
indicates that AR and ERα  contribute to hepatocarcinogenesis in an antagonistic 
way regulating gene expression (Fig. 3): the first stimulates while the second 
restrains proliferation and nucleotide/ amino acid metabolism 83. Such estrogen 
induced resistance and androgen mediated enhancement of tumorigenesis is 
dependent on FOXA1 and FOXA2 pioneer factors, required for chromatin 
recruitment of nuclear receptors. Ablation of FOXA proteins eliminates gender 
differences converting the tumor suppressive role of estrogen into tumor promoting 
83. Estrogens exert a protective function reducing the production of inflammatory 
mediators like IL6 84. However, important estrogen effects on liver physiology can 
also be mediated by its effects on the gonadal-hypophyseal axis 85, 86. In rodents, 
hypophysectomy abolishes sex-dependent differences in HCC 87. Estrogen can 
modulate growth hormone signaling acting on pituitary GH secretion 88, as well as 
on control of GH receptor (GHR) expression 89. GH in turn targets the liver in a sex-
specific manner, which is particularly evident in rodents at puberty, but is also 
found in humans 90. GH function is mediated by the transcriptional activator STAT5, 
which can protect hepatocytes from chronic injuries and malignant transformation 
12, providing another possible mechanism for sexual dimorphism in HCC 
development.  
The lesser susceptibility of women to HCC can also result from estrogen 
stimulated secretion of prolactin, another pituitary-secreted hormone 10, 11. In this 
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context, prolactin may protect females from liver tumorigenesis by restricting 
innate immunity signaling in hepatocytes, which may be of special relevance for the 
virally-associated forms of the disease 10. More specifically, prolactin stimulation of 
hepatic cell lines was shown to suppress response to IL1R, TLF4 and TNFR1 
activation by a post-transcriptional mechanism, thereby suppressing c-Myc 
activation 10.  
 Several other cancer types exhibit higher incidence and aggressive behavior 
in the male and post- versus pre-menopausal female populations, with similar 
gender differences occurring in corresponding animal models. These include colon 
cancer, gliomas, melanoma and non melanoma skin cancer, head/neck squamous cell 
carcinoma (SCC), esophageal and non small cell lung cancer (NSCLC). Protection in 
women extends to hematological malignancies, especially lymphomas, even after 
menopause 1, 2. 
 In many cases, higher estrogen signaling, leading to ERβ activation, has been 
implicated as the likely explanation. ERβ expression is often diminished in these 
various cancer types and sustained ERβ proliferation is a favorable prognostic 
marker. In colon cancer, a polymorphism in the ERβ promoter, possibly influencing 
its activity levels, has been associated with increased survival 91. Polymorphisms in 
the EGFR gene have also been identified that are positively associated with colon 
cancer survival in women and negatively in males 92, pointing to a possible interplay 
between EGFR and ERβ signaling underlying the differences between the two sexes. 
 In skin and head/neck SCC cells in which ERβ expression is down-modulated, 
increased ERβ expression and/or agonist-specific stimulation promotes 
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differentiation through induction of NOTCH1 gene transcription and function 19.  
Also in melanoma, ERβ expression levels are inversely related to primary cancer 
progression in both men and women 93 and, in a mouse model of the disease, 
tamoxifen treatment significantly inhibited metastatic spread in female animals 94. 
ERβ function is required for normal lung and colon morphogenesis 24, 25 and its 
activation exerts beneficial consequences in experimental models of colon 95, glioma 
96, mesothelioma 97, renal cell carcinoma (RCC) 98 and T cell lymphoma 99. 
 In contrast to the above tumor types, the incidence of thyroid cancer is 
significantly higher in the female than male populations. Even though several 
studies tried to find associations between this neoplasm and hormonal or dietary 
factors, the reasons for this discrepancy are still unclear 3. However, experimentally, 
it should be noted that AR expression in thyroid follicular cells was reported to 
reduce proliferation 100, while estrogen treatment induced proliferation and 
suppressed apoptosis 101, suggesting a possibly opposite role of sex hormones in this 
context. 
 
Influence of sex chromosomes on oncogenesis 
 
 The most significant genetic differences between the two sexes reside in the 
X and Y chromosomes. As discussed below, mutations and/or epigenetic 
deregulation of genes on sex chromosomes could contribute to the oncogenetic 
process. Besides protein-encoding genes, deregulated expression of non-coding 
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RNAs is likely to be involved, with a likely interplay with sex hormone action, 
including the fact that the androgen receptor gene is X-linked (Fig. 4).   
 
a) X chromosome 
 To counteract differences in X chromosome gene dosage, mammals utilize 
the X inactivation (Xi) process, involving transcriptional silencing and chromatin 
compaction promoted by the long non coding RNA (lncRNA) Xist 102, 103. Female 
tissues are mosaic for most X-linked genes, resulting from Xi in every cell. Although 
inactivation of one X chromosome over the other is generally random, preferential 
inactivation of one chromosome (skewed Xi) can protect women against the 
consequences of X-linked gene mutations 104. On the contrary the absence of Xi can 
have detrimental effects: for instance loss of Xist has been reported in breast, 
ovarian and cervical cancer cell lines 105, 106 and, only in female mutant mice, it 
caused deregulation of hematopoietic lineages and emergence of myeloid 
neoplasms associated with genome wide changes in gene expression 107.  
 In other settings, cancer development has been linked to increased rather 
than decreased Xist expression. Xist expression can be up-regulated in glioblastoma 
cells of both sexes and its knockdown results in tumour-suppression 108. In 
testicular tumors, increased Xist expression is also frequently observed, which is not 
coupled with methylation of X linked genes, indicating that its role may be distinct 
from this process 109.  
 Despite the X chromosome-wide silencing mechanism, there are regions 
escaping Xist-dependent inactivation. Besides the pseudoautosomal regions (PAR), 
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which have corresponding regions of homology on the Y chromosome, other single 
genes escaping inactivation are spread throughout the chromosome. In particular, 
UTX (KDM6A) is a H3K27 demethylase expressed from both X chromosomes 110. In 
men, UTX has a homolog on the Y chromosome, called UTY (KDM6C), whose 
catalytic activity is very low or absent 111. UTX has a tumor suppressing function and 
inactivating mutations in this gene are not compensated by UTY (Fig. 4). This 
appears to be of importance in human T-acute lymphocyte leukemia (ALL), a 
childhood tumor more common in males than in females and a corresponding 
experimental model of the disease 112-114. Additional X-linked players altered in T-
ALL are the PHF6 and RPL10 genes, which are mutated almost exclusively in male 
patients 115, 116. Loss-of-function UTX mutations have also been found in 
oesophageal SCCs and renal cell carcinomas, which are more frequent in the male 
population 117, 118. Group 4 medulloblastomas are also more prevalent in males and 
it is noteworthy that, besides UTX, several other mutated oncogenes and tumor 
suppressor genes in these tumors are located on the X chromosome 119 (suppl. Table 
1). These include the genes for a component of histone-deacetylase complexes, 
ZMYM3, and the RNA helicase DDX3X, which has a homologue on the Y chromosome 
that is not translated. While ZMYM3 is mutated exclusively in male patients’ tumors, 
DDX3X is also found to be mutated in females’ tumors, in the allele that escapes X 
inactivation 120. Loss of function mutations in DDX3X are also observed in Natural 
killer/T-cell lymphoma (NKTCL) 121 and NSCLC, where the absence of the helicase 
promotes malignancy 122.  
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Other tumor suppressor genes mapping in the X chromosome include WTX, 
which is involved in pediatric kidney cancer Wilms tumors 123, and KDM5C, coding 
for a histone demethylase, whose truncating mutation are found in renal carcinoma 
cells and trigger genomic instability 124 (suppl. Table 1). Of note, KDM5C is also 
overexpressed in HCCs in which it seems to play a pro-oncogenic function 125. 
As mentioned, foxp3 is a X-linked gene, which plays an important role in the 
immune system, by controlling transcription of regulatory T cells. Besides Tregs, 
expression of this gene has been observed in different tumor cells, like lung, 
melanoma, colon cancer cells 126, as well as pancreatic carcinoma cells 127, which 
share some Foxp3-dependent immune suppressing functions with Tregs. 
Furthermore, in breast and prostate cancer Foxp3 inhibits NFkB activation, through 
a Foxp3-miR-146-NFkB axis, which promotes tumor suppression and apoptosis 128. 
We further note that a specific member of the SOX family of transcription factors, 
SOX3, is encoded in the X chromosome (Fig. 4). This will be discussed below in the 
context of the Y-encoded SRY gene. 
 
 Besides protein-coding genes and lncRNAs like Xist, the X chromosome is 
also highly enriched in miRNAs, whose density is almost two-fold higher than in the 
autosomes (suppl. Table 1). Among these are miR-221 and miR-222, which function 
as oncomiRs through repression of the cell cycle inhibitor p27 129. Interestingly, 
these two miRs map relatively close to KDM6A gene, raising the possibility that they 
may also escape Xi. Together with miR-222, miR-223 (also X-linked) is up-regulated 
in gastric cancer, promoting cancer cell migration and metastasis 130. Expression of 
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two other X-linked miRs, miR-20b and miR-361, has potential prognostic 
significance for oropharyngeal carcinoma 131. There is also a cluster of several miRs 
(miR-506, miR-507, miR-508, miR-513a-1, miR-513a-2, miR-513b, and miR-513c) 
that might fine-tune the response of cells to PI3K/Akt activation. Expression of these 
miRs is under direct control of the Akt-dependent FOXO1 and FOXO3 transcription 
factors. In turn, the miRs target these transcription factors as well as components of 
the PI3K and of MAPK cascade 132. 
 Although all these miRs map to the X chromosome, whether or not their 
differential expression contributes to gender differences in cancer risk remains to 
be established.  
 
b) Y chromosome 
 
 Broad as well as restricted alterations of the Y chromosome are frequent in 
cancer development. Loss of the entire Y chromosome (LOY) has been reported with 
various frequencies in prostate 133-135, pancreatic 136, colorectal 137 and bladder 138, 
which has also a strong male prevalence. Short arm deletions have also been found 
in numerous cancer types 139 (http://cgap.nci.nih.gov/Chromosomes/Mitelman). 
Importantly, Y chromosome loss occurs also in normal tissues; it is frequently 
observed in normal hematopoietic cells of elderly men and is significantly 
associated with a greater risk of cancer 140, 141. Y chromosome loss in blood cells 
could be used as predictive biomarker and is also induced by smoking 141.  However, 
it remains to be determined whether or not widespread loss of Y chromosomal regions 
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promotes cancer development or simply results from elimination of unnecessary genetic 
material, as proposed during evolution142. 
 More limited alterations of the Y chromosome can also occur. Of likely 
importance are those affecting the pseudoautosomal region and the closely located SRY 
gene, responsible for male sex development 143. Chromosomal amplifications of the 
pseudoautosomal region Y11p2 adjacent to SRY (located at Y11p3) have been found in 
human HCCs 144 possibly contributing to gender disparity in HCC. Indeed SRY ablation 
can impair development of this cancer type 145, decreasing also chemoresistance 144 
(Figure 3). SRY codes for a HMG box transcription factor of the SOX family. 
Among various members, SRY shares a significant amount of homology with Sox1, 2 
and 3, and may have evolved from these 146. Like Sox2 147, SRY is likely to play a role 
in cancer stem cell renewal, as suggested by its control of OCT4 expression (Fig. 4), 
another key cell reprogramming and stem cell factor 144 and of a c-Myc coactivator, 
sgf29 145. Interestingly, together with these growth promoting functions, SRY has also 
been reported to negatively regulate AR gene transcription through some as yet 
unclarified mechanism 148.  
 TSPY is another Y-linked gene, coding for a SET/NAP (SET proto-oncogene 
/nucleosome assembly protein), with a known function in male germ cell 
differentiation, mitosis, and meiosis 149. Increased TSPY expression occurs in 
testicular germ cell tumors 149, as well as various types of somatic cancer, including 
melanoma 150, prostate 151 and liver cancer 152. Interestingly, while TSPY appears to 
exert a pro-oncogenic function, it has a homologue on the X chromosome, TSPX, 
which can be tumour suppressive 153 and protects from hepatitis B viral infection, a 
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major risk for HCC 154. In fact, both ectopic TSPY activation and TSPX silencing can 
contribute to the initiation and progression of hepatocellular carcinoma, which, as 
discussed in a previous section, is a male-predominant cancer 152 (Fig. 3). In these 
tumors, there is a positive correlation between TSPY and AR expression, with TSPY 
promoting AR expression 155. Conversely, at least in prostate cancer cells, AR 
stimulation by androgen leads to TSPY up-regulation 156. 
 Finally, RBMY (RNA binding motif gene on the Y chromosome) codes for a 
male germ cell-specific regulator of RNA splicing involved in spermatogenesis. 
RBMY is aberrantly activated in male HCC 157, where, like TSPY, it can enhance AR 
expression and activity as well as cancer development 158 (Fig. 3).  
 
Conclusions and future perspectives  
 
 Sex-specific differences in cancer incidence and mortality across ethnic 
backgrounds point to significant influences of gender on both cancer initiation and 
progression (Fig. 1).  An important notion is that cancer as a disease is not limited to 
a group of genetically deranged cells and their immediate environment, but is linked 
to general alterations in organ homeostasis as a result of perturbed 
developmental/morphogenetic signals and systemic factors 43, 159. Selection of cells 
with cumulative somatic mutations 160 or a “Big Bang” expansion of single cell 
populations with pre-existing dominant alterations 161 have been implicated in 
cancer development. However, there can be clonal expansion of cells harboring 
many cancer driver mutations without any clinical signs of the disease 162. Indeed, in 
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most cases, premalignant lesions do not progress into malignancy for reasons that 
are poorly understood 163, 164. This led to the view of an “ecological cellular 
environment” playing a key role in restraining or unleashing tumor growth 164, 165.  
As discussed throughout this review, sex hormones and sex chromosome-encode 
information can impact on all aspects of the cancer process (Fig. 5).  
 As for the tumor cells themselves, important molecular insights can be 
provided by recent developments in large-scale genome sequencing of tumors 
coupled with epigenetic, transcriptomic and proteomic analysis and associated 
clinical information. For instance, analysis of the TCGA database showed differences 
in the mutational landscape of Head/Neck SCCs in the male versus female 
populations, with distinct gene expression profiles 19. It will be interesting to assess 
whether similar differences apply to other cancer types, possibly in a cell type or 
cancer subtype-specific manner, and to determine whether subsets of cancer 
patients with mutational and/or gene expression profiles closer to those of the 
other gender can be identified, with distinct clinical behavior.  
 At the level of the cancer stroma and organ homeostasis, sex hormone 
regulation of angiogenesis stands out as a key element of divergent cancer 
progression between the two sexes, as does inflammation. Systemically, the most 
promising area where understanding sex bias can be of value is at the level of the 
immune system. Immunotherapy based on immune checkpoint inhibitors is rapidly 
emerging as a key therapeutic mainstay of cancer types with high gene mutation 
frequencies 166, most of which exhibit much greater incidence in the male than 
female populations. As we discussed, sex hormone modulation of the immune 
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system can be involved as well as X-linked expression of cytokine genes and 
immune-modulatory miRNAs. It will be important to assess to what extent these 
elements have an impact on key immune checkpoints, like the PD-1/PD-L1 axis, 
acting on various T cell populations, neighboring immunomodulatory cells and 
cancer cells themselves.  
 Sexual dimorphisms that favour females are also observed in lifespan and 
aging 167. Such differences are once again defined by multiple elements. Sex 
hormones, especially estrogens, can play an important role in control of cellular 
senescence and aging-associated tissue deteriorations. Concomitantly, at the 
chromosomal level, it has been suggested that X-linked mutations are more likely to 
exert detrimental effects in male than female cells, which have the advantageous 
possibility of selective inactivation of the mutations-carrying X chromosome 104.  
 Besides its basic value, detailed knowledge of the impact of sex hormones on 
cancer development in organs of non reproductive function has translational 
importance, given the available pharmacological tools to either enhance or suppress 
their function.  This is especially true for steroid hormones 168, 169. Along these lines, 
a topic of great interest and translational potential is that of the interplay between 
their influence and epigenetic reprogramming of cells, with a well known interplay 
between ER and AR function and key histone and DNA modifying enzymes 13, which 
can be targeted by a large battery of natural and synthetic compounds 170. 
Interventions at this level are going to be of great promise for both cancer 
prevention and treatment.  
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Figure legends 
 
Figure 1. Gender differences in cancer incidence and mortality in organs 
unrelated to reproductive function. 
Incidence (A) and mortality (B) rates of various cancer types for the year 2012 in 
males (M) and females (F) of European, African, Americas and South East Asian 
regions. Rates (number of cases per 1000) are for all ages and were retrieved from 
GLOBOCAN 2012 (IARC) (http://globocan.iarc.fr).  
 
Figure 2. Role of sex steroid hormone receptors in non reproductive tissues. 
Summary scheme of the complexity of biological functions of the three sex steroid 
hormone receptors that have been so far implicated. As discussed in the text, 
activation of ERα elicits hematopoietic stem cell expansion and mobilization, favors 
skin wound healing enhancing keratinocyte proliferation, promotes blood vessel 
formation and endothelial cell precursor mobilization, reduces liver cell 
proliferation and restrains the inflammatory role of macrophages. ERβ also blocks 
macrophage activation and, contrary to ERα, negatively regulates angiogenesis. ERβ 
promotes differentiation and suppresses tumor formation in several districts such 
as the skin (acting on both keratinocytes and melanocytes) and is required for the 
proper morphogenesis of lung and colon. AR suppresses wound healing, promotes 
angiogenesis, liver cell proliferation as well as macrophage activation. Androgens 
activity is not limited to AR activation. In fact, through the action of aromatase, they 
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are converted into estrogens, thus controlling indirectly hematopoietic stem cell 
expansion through ERα activity. 
 
Figure 3. Possible mechanisms contributing to gender dimorphism in 
hepatocellular carcinoma (HCC). 
Diagrammatic summary of factors implicated in the greater incidence of HCC in the 
male versus female populations. At hormonal level, AR and ERα activation have 
opposing effect on hepatocytes proliferation and nucleic acid metabolism, acting on 
gene transcription. Estrogen exerts also indirect effects through stimulation of 
prolactin and growth hormone (GH) secretion by the pituitary gland, with these 
hormones in turn suppressing inflammatory and proliferative signals in the liver. At 
the chromosomal level, the X-linked gene TSPX protects from hepatitis B viral 
infection, a major risk for HCC development and loss of TSPX has been observed in 
male patients with HCC. On the other hand, TSPY, the TSPX homolog gene on Y 
chromosome, induces AR expression and is found ectopically expressed in HCC male 
patients. Amplification of two other Y-linked genes, RBMY and SRY, occurs in HCC, 
with RBMY enhancing AR expression and SRY promoting tumorigenesis as well as 
chemo-resistance.  
 
Figure 4. Interplay between sex chromosomes in human cancer. 
Representative illustration of X- and Y-linked genes of functional significance 
discussed in the text. In women, some parts of the X chromosome escape Xist-
mediated inactivation, as is the case for the tumor suppressor gene UTX, which is 
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not compensated by its Y homologue UTY, resulting in differential gene dosage 
effects with likely cancer-protective consequences. Three other genes on the Y 
chromosome, SRY, RBMY and TSPY, have the potential of promoting cancer 
development, which may be mediated, in part, by their modulation of X-linked AR 
expression. Increased SRY activity may also drive cancer stem cell expansion 
through increased expression levels of autosomal genes like OCT4.  
 
Figure 5. Hormonal and chromosomal contributions to sexual dimorphism in 
cancer. 
As discussed in the text, a complex interplay exists between sex hormones and X and 
Y chromosomes, with epigenetic control of gene expression as a link. These 
combined factors can differentially affect cancer development at multiple levels: i) 
cancer target cells of origin, through modulation of ubiquitous or cell type specific 
intracellular processes; ii) cancer stroma and surrounding “field cancerization” 
tissues, through angiogenesis and inflammation; iii) systemically, through 
alterations of the immune system and metabolism. It can be further proposed that 
drug targeting of sex hormone action and associated epigenetic control mechanisms 
can have beneficial effects for multiple cancer types, well beyond those of organs 
with reproductive functions. 
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